142 related articles for article (PubMed ID: 36639243)
1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS
Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans.
Jurva U; Weidolf L; Sandinge AS; Leandersson C; Ekdahl A; Li XQ; Antonsson T; Sundell J; Westerlund K; Amilon C; Inghardt T; Gopaul VS
Drug Metab Dispos; 2023 Apr; 51(4):464-479. PubMed ID: 36653117
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling.
Wen B; Zhang Y; Young GC; Kenworthy D; Pereira A; Pirhalla J; Doyle J; Jordon B; Zhan J; Johnson M
Drug Metab Dispos; 2022 Nov; 50(11):1442-1453. PubMed ID: 36153007
[TBL] [Abstract][Full Text] [Related]
4. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
[TBL] [Abstract][Full Text] [Related]
7. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Gan LM; Lagerström-Fermér M; Ericsson H; Nelander K; Lindstedt EL; Michaëlsson E; Kjaer M; Heijer M; Whatling C; Fuhr R
Br J Clin Pharmacol; 2019 Apr; 85(4):762-770. PubMed ID: 30618054
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [
Yang Z; Wong SL; Cha D; Wilfret D; Turnquist D; Plummer A; van Ingen E; Kearney BP
Drug Metab Dispos; 2023 Dec; 51(12):1607-1614. PubMed ID: 37684056
[TBL] [Abstract][Full Text] [Related]
11. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [
Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H
Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation Pathways and Metabolite Profiles of Oral [
Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
[TBL] [Abstract][Full Text] [Related]
13. Proof of Concept: First Pediatric [
van Groen BD; van Duijn E; de Vries A; Mooij MG; Tibboel D; Vaes WHJ; de Wildt SN
Clin Pharmacol Ther; 2020 Nov; 108(5):1003-1009. PubMed ID: 32386327
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
16. Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K; Lagerstrom-Fermer M; Amilon C; Michaëlsson E; Heijer M; Kjaer M; Russell M; Han D; Lindstedt EL; Whatling C; Gan LM; Ericsson H
Clin Transl Sci; 2021 May; 14(3):812-819. PubMed ID: 32770730
[TBL] [Abstract][Full Text] [Related]
17. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
18.
Ma J; Laskin OL; Roffel AF; Vaes WHJ; Tang B; Kolnaar J; O'Keefe K; Golden L; Kong R
Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37852795
[TBL] [Abstract][Full Text] [Related]
19. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L
Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543
[TBL] [Abstract][Full Text] [Related]
20. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
